Search API

Urinary Tract Infection (UTI) Clinical Trials

Urinary Tract Infection (UTI) Vaccine Clinical Trials 2025

Clinical trials for a urinary tract infection (UTI) vaccine and treatment are being conducted in 2025. To register for a clinical trial, please visit this Clinical Trials Link. This GSK UTI vaccine candidate study is seeking participants in the United States, Argentina, Belgium, South Africa, and Spain.

Recurrent UTI Vaccine Information

Uromune™ (MV140) is a self-administered oral spray vaccine for recurrent urinary tract infections approved for adults in certain countries. A vaccination appointment can be requested at PassportHealth.

Urinary Tract Infection Treatments

In March 2025, the US FDA approved Blujepa (gepotidacin) for the treatment of female adults (≥40 kg) and paediatric patients (≥12 years, ≥40 kilograms) with uncomplicated urinary tract infections caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus, and Enterococcus faecalis.

RECCE® 327 is an intravenous and topical therapy developed to treat serious UTI/Urosepsis infections caused by Gram-positive and Gram-negative bacteria, including their superbug forms.

UTILITY therapeutics Ltd. pivmecillinam (Pivya™, Selexid, Melysin, Coactab) tablets are approved for the treatment of female adults with uncomplicated UTIs. Pivmecillinam is expected to be available in the USA in 2025.

UTI Vaccine Appointment Requests

UTI vaccination requests can be submitted using this appointment link.

2 min read
Reviewer: 
Robert Carlson, MD
Last Reviewed: 
Thursday, December 11, 2025 - 08:55
Description: 
Urinary Tract Infection (UTI) vaccine and treatment clinical trials are being conducted in 2025
Condition: 
Urinary Track Infection (UTI)
Vaccine: 
Uromune MV140 Urinary Tract Infection Vaccine
0 min read

According to a new report from the European Centre for Disease Prevention and Control (ECDC), more than 25,000 cases of pertussis and 19 related deaths were reported in 2023, and more than 32,000 between January and March 2024.

The ECDC data announced on May 8, 2024, indicates a nearly 10-fold increase in pertussis (whooping cough) cases compared with 2022.

Historically, infants have had the highest incidence of pertussis reported in European countries. However, in 2023–24, an increase among infants has been observed, along with large increases in 10–14 and 15– 19-year-olds.

According to information from open sources, an increase in pertussis cases has also been reported in many countries in 2024, including Australia, Brazil, Canada, Israel, the United States, and the United Kingdom.

The primary objective of national pertussis immunization programs should be to curb morbidity and mortality in newborn infants. 

To this end, and given the ongoing pertussis outbreaks, the ECDC encourages all public health authorities to focus on achieving and sustaining high vaccination coverage through timely and full completion of pertussis primary immunization series and subsequent boosters recommended nationally.

The World Health Organization and numerous agencies have approved various pertussis vaccines.

Vaccine Treats: 
Pertussis
Image: 
Image Caption: 
ECDC Pertussis case trends May 8, 2024
Live Blog Update Author: 
Karen McClorey Hackett
Location Tags: 
Netherlands
Vaccine: 
Boostrix Pertussis Vaccine
Include in VBT newsletter: 
malaria

Los Angeles Malaria Outbreak Arrived From the South

Malaria vaccines are unavailable in the United States
May 8, 2024
0 min read

A recent study aimed to compare the positive benefits between two U.S. FDA-approved influenza antiviral medications.

Published in the journal Influenza and Other Respiratory Viruses on May 6, 2024, this study concluded that Xofluza (baloxavir marboxil, BMX) appears to be more effective than Tamiflu (oseltamivir, OTV) in lowering the secondary attack rate.

The Poisson regression modeling showed that in those cases treated with BXM and OTV, the benefits were 10.8% and 18.5%, respectively; the adjusted relative reduction was 41.8% (95% confidence interval: 1.0%–65.7%, p = 0.0456) greater with BXM than OTV. 

These researchers wrote that one reason for this result may have been the difference in administration: a single dose of BXM versus twice daily for five days for OTV. Thus, BXM is expected to have higher compliance than OTV in children.

In summary, this post hoc analysis found that the secondary influenza illness attack rate was lower in household contacts exposed to BXM-treated than OTV-treated index cases.

Vaccine Treats: 
Influenza
Image: 
Image Caption: 
from Pixabay
Live Blog Update Author: 
Karen McClorey Hackett
Location Tags: 
Austin
Vaccine: 
Flumist Quadrivalent Influenza Vaccine
Include in VBT newsletter: 
0 min read

According to Reuters reporting, AstraZeneca is voluntarily withdrawing its COVID-19 vaccine Vaxzevria as global demand has declined in 2024.

The University of Oxford, Serum Institute of India Pvt. Ltd., and AstraZeneca co-produced Vaxzevria COVID-19 (AZD1222). The European Medicines Agency initially authorized Vaxzevria in February 2021.

The London-based company indicated that the decision to pull Vaxzevria from the global market was due to the "surplus of available updated vaccines" adapted to newer and emerging variants of COVID-19, Reuters reported on May 6, 2024.

"We are incVaxzevria's role Vaxzevria played in ending the global pandemic. According to independent estimates, over 6.5 million lives were saved in the first year of use alone, and over three billion doses were supplied globally," AstraZeneca told The Telegraph in a statement.

Over the past month, other COVID-19 vaccine producers have reported significant decreases in consumer demand.

In the U.S., the Food and Drug Administration recently announced it intends to issue its recommendations for 2024-2025 COVID-19 vaccines in mid-June 2024.

Vaccine Treats: 
COVID-19
Image: 
Image Caption: 
by Leigh P.
Live Blog Update Author: 
Karen McClorey Hackett
Location Tags: 
London
Vaccine: 
Vaxzevria COVID-19 Vaccine
Include in VBT newsletter: 
0 min read

ImmunityBio, Inc. announced today that the drug substance had been completed and successfully qualified for “fill finish” (filling vials and finishing packaging), sufficient for 170,000 doses of 400mcg ANKTIVA®.

ANKTIVA (nogapendekin alfa inbakicept-pmln) is the first U.S. FDA-approved immunotherapy for non-muscle invasive bladder cancer that activates natural killer cells, T cells and memory T cells for a long-duration response.

Coupled with the recent announcement of a partnership with the Serum Institute of India for enhanced BCG vaccine availability, this provides the Company with a significant initial supply of ANKTIVA for commercial and clinical trial use in advance of the full operation of the Company’s drug substance and fill-finish manufacturing plants in California and New York.

In 2024, Anktiva will be priced at $35,800 per dose. The cost of the BCG vaccine is additional.

Since the Company’s merger with NantKwest in 2021, ImmunityBio has made significant capital investments in personnel, plants, and equipment to ensure the global capacity of the ANKTIVA drug product for both the commercial launch and clinical trials in bladder cancer and other tumor types in its pipeline.

Both drug substance and drug product facilities are nearing completion to ensure sufficient capacity and multiple GMP manufacturing sites for ANKTIVA in its approved indication and for clinical trials and future indications.

“Our belief in the importance of this molecule and its potential to evolve immunotherapy to the next level guided our strategic plan to invest for the future with anticipation of ANKTIVA’s approval,” said Rich Adcock, CEO & President ImmunityBio, in a press release on May 7, 2024.

“I’m grateful for our employees and our investors who have supported and believed in our commitment to invest for our long-term vision and future.”

The Company is applying its science and platforms to treating cancers, including developing potential cancer vaccines, immunotherapies, and cell therapies that we believe will sharply reduce or eliminate the need for standard high-dose chemotherapy.

TCompany says these platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.

Vaccine Treats: 
Bladder Cancer
Image: 
Image Caption: 
by Gerd Altmann
Live Blog Update Author: 
Don Hackett
Location Tags: 
Culver City
Vaccine: 
Anktiva N-803 plus BCG Vaccine
Include in VBT newsletter: 
0 min read

The U.S. Food and Drug Administration (FDA) today announced on X a change of date for its May 16, 2024, Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting.

The VRBPAC is now scheduled to meet on June 5, 2024, to recommend the inclusion of the SARS-CoV-2 coronavirus strain(s) in the 2024-2025 COVID-19 vaccines.

@FDACBER stated the VRBPAC will have more up-to-date information when discussing and making recommendations.

This advisory committee provides independent expert advice to the FDA on broad scientific topics or certain products to help the agency make sound decisions based on the available science. 

As of 2024, about 50 COVID-19 vaccines have been approved globally since the pandemic began in late 2019. SKYCovione™ became the 12th, and CORBEVAX®  the 13th COVID-19 vaccine granted authorization by the WHO.

Vaccine Treats: 
COVID-19
Image: 
Image Caption: 
US FDA May 2024
Live Blog Update Author: 
Don Hackett
Location Tags: 
Silver Spring
Vaccine: 
Novavax COVID-19 Vaccine
Include in VBT newsletter: 
malaria

How Many Malaria Vaccinations Are Needed

Mosquirix RTS, S/AS01 (RTS,S) is an approved recombinant malaria vaccine
May 7, 2024
vaccine

Proactive Vaccinology Builds Vaccines Before Pathogens Emerge

Quartet Nanocage vaccine is based on a structure called a nanoparticle
May 7, 2024
0 min read

Valneva SE today reported its financial results for the first quarter ending March 31, 2024, and provided corporate updates.

On May 7, 2024, the Company announced IXCHIQ®, the world's first and only licensed chikungunya vaccine, recorded initial sales of €0.2 million in the first quarter in the U.S.

In a press release, Peter Bühler, Valneva's Chief Financial Officer, commented, "The first quarter performance has been in line with our expectations. We are aiming to further capitalize on the travel industry recovery during the rest of the year (2024), including ramping up sales for IXCHIQ® to support our commercial sales growth while executing on our key R&D milestones."

IXCHIQ® is also under regulatory review in Canada, Brazil, and Europe, where it was granted accelerated assessment by the European Medicine Agency's Committee for Medicinal Products for Human Use. Decisions on these submissions are expected in 2024.

The U.S. Centers for Disease Control and Prevention (CDC) recently adopted the U.S. Advisory Committee on Immunization Practices recommendations, which include the chikungunya vaccine for persons aged ≥18 traveling to a country or territory with a chikungunya outbreak. 

In addition, the CDC says the chikungunya vaccine may be considered for those traveling to a country or territory without an outbreak but with evidence of chikungunya virus transmission among humans within the last five years. 

Persons aged >65 years, particularly those with underlying medical conditions, are likely to have at least moderate exposure* to mosquitoes OR Persons staying for a cumulative period of 6 months or more. Moderate exposure could include travelers with at least two weeks (cumulative) of exposure to mosquitoes in indoor or outdoor settings.

Chikungunya is a viral disease transmitted to humans through the bites of mosquitoes infected with the chikungunya virus.

As of May 2024, the World Health Organization says chikungunya was identified in nearly 115 countries, primarily in the Region of the Americas.

According to the European Centre for Disease Prevention and Control, approximately 70,000 chikungunya cases and 15 deaths have been reported worldwide in 2024.

Vaccine Treats: 
Chikungunya
Image: 
Image Caption: 
ECDC chikungunya case map April 2024
Live Blog Update Author: 
Karen McClorey Hackett
Location Tags: 
Saint-Herblain
Vaccine: 
IXCHIQ Chikungunya Vaccine Live
Include in VBT newsletter: